Pancreatic Cancer Research

ResearcherAsan Medical CenterActive in the last 2 years

Seung Soo Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-5518-2249; OpenAlex author ID A5013428392, A5056046654. Sources: OpenAlex.

Their work

Papers
23 (first author 4, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 2 papers · 2019: 1 paper · 2020: 2 papers · 2021: 4 papers · 2022: 3 papers · 2023: 3 papers · 2024: 2 papers · 2025: 2 papers · 2026: 3 papers

Papers 23

  1. Differentiating large-duct pancreatic ductal adenocarcinoma from malignant intraductal papillary mucinous neoplasm: MRI characteristics and diagnostic implicat… Co-author DOI 10.1016/j.ejrad.2026.112735↗
  2. Modified FOLFIRINOX with or Without Stereotactic Body Radiation in Locally Advanced Unresectable Pancreatic Cancer (SABER): A Randomized Open-Label Phase 2 Tri… Co-author DOI 10.1245/s10434-026-19762-3↗
  3. Updates on Imaging Assessment of Pancreatic Cancer for Determining Anatomic and Biologic Resectability. Co-author DOI 10.3348/kjr.2026.0341↗
  4. Survival Outcomes According to NCCN Criteria for Resection Following Neoadjuvant Therapy for Patients with Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16437-9↗
  5. ASO Author Reflections: Prognostic Value of NCCN Criteria for Resection Following Neoadjuvant Therapy in Localized Pancreatic Cancer. Co-author DOI 10.1245/s10434-024-16618-6↗
  6. Comparison of the different versions of NCCN guidelines for predicting margin-negative resection of pancreatic cancer in patients undergoing upfront surgery. Co-author DOI 10.1007/s00261-024-04299-4↗
  7. Predicting Recurrence-Free Survival After Upfront Surgery in Resectable Pancreatic Ductal Adenocarcinoma: A Preoperative Risk Score Based on CA 19-9, CT, and 1… Co-author DOI 10.3348/kjr.2023.1235↗
  8. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study. Co-author DOI 10.1007/s00330-023-09584-2↗
  9. Pancreas CT assessment for pancreatic ductal adenocarcinoma resectability: effect of tube voltage and slice thickness on image quality and diagnostic performan… First author DOI 10.1186/s40644-023-00637-9↗
  10. Large Duct Pancreatic Ductal Adenocarcinoma: A Morphological Variant of Pancreatic Ductal Adenocarcinoma With Distinct CT and MRI Characteristics. Co-author DOI 10.3348/kjr.2023.0521↗
  11. Prediction of margin-negative resection of pancreatic ductal adenocarcinoma following neoadjuvant therapy: Diagnostic performance of NCCN criteria for resectio… Co-author DOI 10.1002/jhbp.1192↗
  12. Preoperative data-based deep learning model for predicting postoperative survival in pancreatic cancer patients. Co-author DOI 10.1016/j.ijsu.2022.106851↗
  13. Prognostic Value of Sarcopenia and Myosteatosis in Patients with Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3348/kjr.2022.0277↗
  14. Systematic review and meta-analysis of diagnostic performance of CT imaging for assessing resectability of pancreatic ductal adenocarcinoma after neoadjuvant t… Co-author DOI 10.1007/s00261-021-03198-2↗
  15. Multiparametric MRI for prediction of treatment response to neoadjuvant FOLFIRINOX therapy in borderline resectable or locally advanced pancreatic cancer. First author DOI 10.1007/s00330-020-07134-8↗
  16. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy. Co-author DOI 10.1007/s00330-020-07188-8↗
  17. CT in the prediction of margin-negative resection in pancreatic cancer following neoadjuvant treatment: a systematic review and meta-analysis. Co-author DOI 10.1007/s00330-020-07433-0↗
  18. Neoadjuvant modified FOLFIRINOX followed by postoperative gemcitabine in borderline resectable pancreatic adenocarcinoma: a Phase 2 study for clinical and biom… Co-author DOI 10.1038/s41416-020-0867-x↗
  19. Estimating Recurrence after Upfront Surgery in Patients with Resectable Pancreatic Ductal Adenocarcinoma by Using Pancreatic CT: Development and Validation of … First author DOI 10.1148/radiol.2020200281↗
  20. Differentiating focal autoimmune pancreatitis and pancreatic ductal adenocarcinoma: contrast-enhanced MRI with special emphasis on the arterial phase. Last author DOI 10.1007/s00330-019-06200-0↗
  21. Comparison of diagnostic performance between CT and MRI in differentiating non-diffuse-type autoimmune pancreatitis from pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s00330-018-5565-1↗
  22. Pancreatic Cancer CT: Prediction of Resectability according to NCCN Criteria. First author DOI 10.1148/radiol.2018180628↗
  23. Diagnostic Strategy for Differentiating Autoimmune Pancreatitis From Pancreatic Cancer: Is an Endoscopic Retrograde Pancreatography Essential? Co-author DOI 10.1097/mpa.0b013e31823a509b↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jae Ho Byun · 16 shared papers, 2012–2026 · strength 2.41
  2. Hyoung Jung Kim · 14 shared papers, 2018–2025 · strength 2.10
  3. Song Cheol Kim · 13 shared papers, 2018–2026 · strength 2.09
  4. Jin Hee Kim · 15 shared papers, 2012–2025 · strength 2.08
  5. Kyu‐pyo Kim · 10 shared papers, 2020–2026 · strength 1.92
  6. Dae Wook Hwang · 8 shared papers, 2020–2026 · strength 1.55
  7. Changhoon Yoo · 9 shared papers, 2020–2026 · strength 1.49
  8. Seung‐Mo Hong · 7 shared papers, 2018–2025 · strength 1.18
  9. Woohyung Lee · 5 shared papers, 2020–2026 · strength 1.11
  10. Jong Keon Jang · 6 shared papers, 2021–2025 · strength 1.05
  11. Ki Byung Song · 6 shared papers, 2018–2026 · strength 0.95
  12. Se Jin Choi · 4 shared papers, 2022–2025 · strength 0.79
  13. Dong‐Wan Seo · 4 shared papers, 2021–2025 · strength 0.68
  14. Baek‐Yeol Ryoo · 3 shared papers, 2020–2026 · strength 0.47
  15. Dong Wook Kim · 3 shared papers, 2020–2023 · strength 0.46
  16. Dong Ho Lee · 2 shared papers, 2023 · strength 0.34
  17. Jeong Min Lee · 2 shared papers, 2023 · strength 0.34
  18. Jin‐hong Park · 2 shared papers, 2020–2026 · strength 0.33
  19. Tae Jun Song · 2 shared papers, 2020–2026 · strength 0.33
  20. Dong Wan Seo · 2 shared papers, 2020–2025 · strength 0.31
  21. Se Jin Choi · 1 shared paper, 2026 · strength 0.28
  22. Ji Hun Kang · 2 shared papers, 2021 · strength 0.25
  23. Hyehyun Jeong · 1 shared paper, 2026 · strength 0.25
  24. Inkeun Park · 1 shared paper, 2026 · strength 0.25
  25. Dongwook Oh · 1 shared paper, 2026 · strength 0.25

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.